Table 4.
Changes of dependent variables (plasma levels of glycemic and insulinemic biomarkers) with BV supplementation in women with BBD
| Variable | Placebo group | BV group | P- value b |
|---|---|---|---|
| Insulin (U/mL) | |||
| Model 1c | 0.54 ± 0.02a | 0.55 ± 0.02 | 0.783 |
| Model 2 d | 0.54 ± 0.02 | 0.55 ± 0.2 | 0.669 |
| C-peptide (ng/mL) | |||
| Model 1 | 2.97 ± 0.07 | 3.33 ± 0.12 | 0.029 |
| Model 2 | 2.96 ± 0.07 | 3.35 ± 0.13 | 0.018 |
| FBS (mg/dL) | |||
| Model 1 | 87.64 ± 0.40 | 94.70 ± 1.24 | < 0.001 |
| Model 2 | 87.70 ± 0.41 | 94.20 ± 1.44 | < 0.001 |
| HOMA-IR e | |||
| Model 1 | 0.13 ± 0.01 | 0.14 ± 0.01 | 0.183 |
| Model 2 | 0.13 ± 0.01 | 0.13 ± 0.01 | 0.633 |
| HOMB f | |||
| Model 1 | 666 ± 78 | 973 ± 147 | 0.114 |
| Model 2 | 664 ± 76 | 977 ± 142 | 0.048 |
| QUIKI g | |||
| Model 1 | 0.66 ± 0.01 | 0.65 ± 0.01 | 0.447 |
| Model 2 | 0.66 ± 0.01 | 0.65 ± 0.01 | 0.359 |
| G:I ratio h | |||
| Model 1 | 0.62 ± 0.02 | 0.63 ± 0.02 | 0.697 |
| Model 2 | 0.62 ± 0.01 | 0.63 ± 0.01 | 0.252 |
a
All data are expressed in geometric mean ± S.E..
b
This p-value obtained from performing ANCOVA.
c
Weighted least square was performed in ANOVA with adjustment for baseline variable (model 1).
d
Model 2 obtained from performing ANCOVA after adjustment for the frequency of lactation (n) and BMI (kg/m2) at baseline in addition to baseline variable.
e
Homeostatic model assessment.
f
Assessment of B-cell functionality.
g
quantitative insulin sensitivity check index.
h
Glucose to insulin ratio.